How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?
DOI:
https://doi.org/10.2340/1651-226X.2025.43645Keywords:
adjuvant therapy, bisphosphonates, CDK4/6 inhibitors, endocrine treatment, PARP inhibitorAbstract
Background and purpose: The prognosis for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer has significantly improved over the past few decades. However, a substantial number of patients still face an elevated risk of recurrence. Due to the high prevalence and cumulative mortality of HR+/HER2- breast cancer, it poses a global health challenge.
Material and methods: This is a narrative review on the post-chemotherapy treatment options in patients with HR+/HER2- breast cancer.
Results: Endocrine therapy remains the cornerstone of adjuvant treatment, with extended durations of tamoxifen and aromatase inhibitors demonstrating survival benefits. Several novel post-chemotherapy adjuvant treatments have recently been introduced for high-risk patients, and now most patients with HR+/HER2- breast cancer are eligible for non-endocrine adjuvant therapies. Bisphosphonates help to reduce bone recurrence and enhance overall survival in postmenopausal women, though the evidence remains somewhat inconsistent. CDK4/6 inhibitors abemaciclib and ribociclib have also emerged as adjuvant therapies, while the poly ADP ribose polymerase (PARP) inhibitor olaparib provides clinically meaningful benefits for patients with germline BRCA1/2 mutations.
Interpretation: Optimal patient selection for these often toxic treatments remains partially unclear and is the focus of intensive research. In the near future, monitoring ctDNA may enable treatment de-escalation for selected high-risk patients. The rise of perioperative immunological therapies, new CDK4-specific inhibitors, and targeted endocrine treatments can lead to a notably favorable prognosis for many previously high-risk HR+/HER2- breast cancers. Future research should prioritize predictive biomarkers and personalized approaches to optimize treatment efficacy, ensure more equal access to treatments, and minimize overtreatment.
Downloads
References
Howlader N, Cronin KA, Kurian AW, Goode EL, Wu AH, Harris HR, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27:619–26.
https://doi.org/10.1158/1055-9965.EPI-17-0627 DOI: https://doi.org/10.1158/1055-9965.EPI-17-0627
Acheampong T, Kehm RD, Terry MB, Argov EL, Tehranifar P. Incidence trends of breast cancer molecular subtypes by age and race/ethnicity in the US From 2010 to 2016. JAMA Netw Open. 2020;3:e2013226.
https://doi.org/10.1001/jamanetworkopen.2020.13226 DOI: https://doi.org/10.1001/jamanetworkopen.2020.13226
Brandão M, Morais S, Lopes-Conceição L, Fontes F, Araújo N, Dias T, et al. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open. 2020;5:e000984.
https://doi.org/10.1136/esmoopen-2020-000984 DOI: https://doi.org/10.1136/esmoopen-2020-000984
Edwards MJ, Gamel JW, Feuer EJ. Improvement in the prognosis of breast cancer from 1965 to 1984. J Clin Oncol. 1998;16:1030–5.
https://doi.org/10.1200/JCO.1998.16.3.1030 DOI: https://doi.org/10.1200/JCO.1998.16.3.1030
Park JH, Anderson WF, Gail MH. Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. J Clin Oncol. 2015;33:2870–6.
https://doi.org/10.1200/JCO.2014.59.9191 DOI: https://doi.org/10.1200/JCO.2014.59.9191
EBCTCG. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials. Lancet. 2024;404:1407–18.
https://doi.org/10.1016/S0140-6736(24)01745-8 DOI: https://doi.org/10.1016/S0140-6736(24)01745-8
Hoxha I, Islami DA, Uwizeye G, Forbes V, Chamberlin MD. Forty-five years of research and progress in breast cancer: progress for some, disparities for most. JCO Glob Oncol. 2022;8:e2100424.
https://doi.org/10.1200/GO.21.00424 DOI: https://doi.org/10.1200/GO.21.00424
Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, et al. The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst. 2022;11:391–9.
https://doi.org/10.1093/jnci/djab202 DOI: https://doi.org/10.1093/jnci/djab202
De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, et al. Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev. 202;109:102434.
https://doi.org/10.1016/j.ctrv.2022.102434 DOI: https://doi.org/10.1016/j.ctrv.2022.102434
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.
https://doi.org/10.1056/NEJMoa1701830 DOI: https://doi.org/10.1056/NEJMoa1701830
Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer. 2008;112:1437–44.
https://doi.org/10.1002/cncr.23320 DOI: https://doi.org/10.1002/cncr.23320
Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17:323–34.
https://doi.org/10.1016/j.breast.2008.02.002 DOI: https://doi.org/10.1016/j.breast.2008.02.002
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113:808–19.
https://doi.org/10.1093/jnci/djaa201 DOI: https://doi.org/10.1093/jnci/djaa201
Petrelli F, Viale G, Cabiddu M, Bardi S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153:477–91.
https://doi.org/10.1007/s10549-015-3559-0 DOI: https://doi.org/10.1007/s10549-015-3559-0
Loibl S, André F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al., on behalf of the ESMO Guidelines Committee. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159–82.
https://doi.org/10.1016/j.annonc.2023.11.016 DOI: https://doi.org/10.1016/j.annonc.2023.11.016
Stendahl M, Rydén L, Nordenskjöld B, Jönsson PE, Landberg G, Jirström KL. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res. 2006;12:4614–8.
https://doi.org/10.1158/1078-0432.CCR-06-0248 DOI: https://doi.org/10.1158/1078-0432.CCR-06-0248
Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial. Ann Oncol. 2007;18:859–67.
https://doi.org/10.1093/annonc/mdm001 DOI: https://doi.org/10.1093/annonc/mdm001
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77:181–5.
https://doi.org/10.1111/his.14091 DOI: https://doi.org/10.1111/his.14091
Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N, et al. Comprehensive review of molecular mechanisms and clinical features of invasive lobular cancer. Oncologist. 2021;26:e943–53.
https://doi.org/10.1002/onco.13734 DOI: https://doi.org/10.1002/onco.13734
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer (Version 1.2025) [Internet]. 2025 [cited 2025 Feb 12]. Available from: https://www.nccn.org
Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375:e066381.
https://doi.org/10.1136/bmj-2021-066381 DOI: https://doi.org/10.1136/bmj-2021-066381
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.
https://doi.org/10.1056/NEJMoa2105215 DOI: https://doi.org/10.1056/NEJMoa2105215
Cognetti F, Biganzoli L, De Placido S, Del Mastro L, Masetti R, Naso G, et al. Multigene tests for breast cancer: the physician’s perspective. Oncotarget. 2021;12:936–47.
https://doi.org/10.18632/oncotarget.27948 DOI: https://doi.org/10.18632/oncotarget.27948
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380:2395–405.
https://doi.org/10.1056/NEJMoa1904819 DOI: https://doi.org/10.1056/NEJMoa1904819
Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–2347.
https://doi.org/10.1056/NEJMoa2108873 DOI: https://doi.org/10.1056/NEJMoa2108873
Piccart M, Van ’t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22:476–88.
https://doi.org/10.1016/S1470-2045(21)00007-3 DOI: https://doi.org/10.1016/S1470-2045(21)00007-3
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25:339–45.
https://doi.org/10.1093/annonc/mdt494 DOI: https://doi.org/10.1093/annonc/mdt494
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, et al. Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2−negative early breast cancer. Ann Oncol. 2013;24:640–7.
https://doi.org/10.1093/annonc/mds334 DOI: https://doi.org/10.1093/annonc/mds334
Cardoso F, Van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.
https://doi.org/10.1056/NEJMoa1602253 DOI: https://doi.org/10.1056/NEJMoa1602253
Kerr AJ, Dodwell D, McGale P, Holt F, Duane F, Mannu G, et al. Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat Rev. 2022;105:102375.
https://doi.org/10.1016/j.ctrv.2022.102375 DOI: https://doi.org/10.1016/j.ctrv.2022.102375
John P, Osani MC, Kodali A, Buchsbaum R, Bannuru RR, Erban JK. Comparative effectiveness of adjuvant chemotherapy in early-stage breast cancer: a network meta-analysis. Clin Breast Cancer. 2021;21:e22–37.
https://doi.org/10.1016/j.clbc.2020.07.005 DOI: https://doi.org/10.1016/j.clbc.2020.07.005
Beatson GT. On the treatment of inoperable cases of carcinoma of the Mamma: suggestions for a new method of treatment, with illustrative cases. Trans Med Chir Soc Edinb. 1896;15:153–79.
Ward HW. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J. 1973;1:13–4.
https://doi.org/10.1136/bmj.1.5844.13 DOI: https://doi.org/10.1136/bmj.1.5844.13
‘Nolvadex’ Adjuvant Trial Organisation. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer. 1988;57:608–11.
https://doi.org/10.1038/bjc.1988.138 DOI: https://doi.org/10.1038/bjc.1988.138
Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–67.
https://doi.org/10.1016/S0140-6736(97)11423-4 DOI: https://doi.org/10.1016/S0140-6736(97)11423-4
Rutqvist LE, Johansson H, Stockholm Breast Cancer Study Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46:133–45.
https://doi.org/10.1080/02841860601034834 DOI: https://doi.org/10.1080/02841860601034834
Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996;88:1543–9.
https://doi.org/10.1093/jnci/88.21.1543 DOI: https://doi.org/10.1093/jnci/88.21.1543
Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst. 1996;88:1834–9.
https://doi.org/10.1093/jnci/88.24.1834 DOI: https://doi.org/10.1093/jnci/88.24.1834
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.
https://doi.org/10.1016/S0140-6736(12)61963-1 DOI: https://doi.org/10.1016/S0140-6736(12)61963-1
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol. 2022;23:382–92.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262–71.
https://doi.org/10.1093/jnci/dji250 DOI: https://doi.org/10.1093/jnci/dji250
Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26:1965–71.
https://doi.org/10.1200/JCO.2007.14.0228 DOI: https://doi.org/10.1200/JCO.2007.14.0228
Tjan-Heijnen VCG, Van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, Van der Sangen MJC, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017;18:1502–11.
https://doi.org/10.1016/S1470-2045(17)30600-9 DOI: https://doi.org/10.1016/S1470-2045(17)30600-9
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Van den Bosch J, et al. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006–05). J Natl Cancer Inst. 2018;110(1):40–8.
https://doi.org/10.1093/jnci/djx134 DOI: https://doi.org/10.1093/jnci/djx134
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–19.
https://doi.org/10.1056/NEJMoa1604700 DOI: https://doi.org/10.1056/NEJMoa1604700
Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, et al. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:88–99.
https://doi.org/10.1016/S1470-2045(18)30621-1 DOI: https://doi.org/10.1016/S1470-2045(18)30621-1
Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T, et al. Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis. EClinicalMedicine. 2025;81:103116.
https://doi.org/10.1016/j.eclinm.2025.103116 DOI: https://doi.org/10.1016/j.eclinm.2025.103116
Shrestha A, Cullinane C, Evoy D, Geraghty J, Rothwell J, Walshe J, et al. Clinical treatment score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis. Br J Surg. 2022;109:411–7.
https://doi.org/10.1093/bjs/znac008 DOI: https://doi.org/10.1093/bjs/znac008
Bae SJ, Moon S, Kook Y, Baek SH, Lee M, Kim JH, et al. Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer. NPJ Breast Cancer. 2025;11:33.
https://doi.org/10.1038/s41523-025-00747-6 DOI: https://doi.org/10.1038/s41523-025-00747-6
Richman J, Ring A, Dowsett M, Sestak I. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2021;186(1):115–23.
https://doi.org/10.1007/s10549-020-06013-6 DOI: https://doi.org/10.1007/s10549-020-06013-6
Sestak I, Buus R, Cuzick J, Dubsky P, Kronenwett R, Denkert C, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:545–53.
https://doi.org/10.1001/jamaoncol.2017.5524 DOI: https://doi.org/10.1001/jamaoncol.2017.5524
Noordhoek I, Treuner K, Putter H, Zhang Y, Wong J, Meershoek-Klein Kranenbarg E, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR+ early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res. 2021;27:311–9.
https://doi.org/10.1158/1078-0432.CCR-20-2737 DOI: https://doi.org/10.1158/1078-0432.CCR-20-2737
Van ’t Veer LJ, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Van de Velde CJH, Kleijn M, Dreezen C, et al. Selection of patients with early-stage breast cancer for extended endocrine therapy: a secondary analysis of the IDEAL randomized clinical trial. JAMA Netw Open. 2024;7:e2447530.
https://doi.org/10.1001/jamanetworkopen.2024.47530 DOI: https://doi.org/10.1001/jamanetworkopen.2024.47530
Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023;41:1376–82.
https://doi.org/10.1200/JCO.22.01064 DOI: https://doi.org/10.1200/JCO.22.01064
Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol. 2023;41:1370–5.
https://doi.org/10.1200/JCO.22.01065 DOI: https://doi.org/10.1200/JCO.22.01065
Ruíz-Borrego M, Guerrero-Zotano A, Bermejo B, Ramos M, Cruz J, Baena-Cañada JM, et al. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006–10 study. Breast Cancer Res Treat. 2019;177:115–25.
https://doi.org/10.1007/s10549-019-05296-8 DOI: https://doi.org/10.1007/s10549-019-05296-8
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022;14:17588359221113694.
https://doi.org/10.1177/17588359221113694 DOI: https://doi.org/10.1177/17588359221113694
Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85.
https://doi.org/10.1186/s13058-021-01462-3 DOI: https://doi.org/10.1186/s13058-021-01462-3
Van den Biggelaar YJPG, Kuiper JG, Van der Sangen MJC, Luiten EJT, Siesling S, Van Herk-Sukel M, et al. 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: a population-based database study (2006–2016). Breast Dis. 2023;42:331–9.
https://doi.org/10.3233/BD-230024 DOI: https://doi.org/10.3233/BD-230024
Heiney SP, Parker PD, Felder TM, Adams SA, Omofuma OO, Hulett JM. A systematic review of interventions to improve adherence to endocrine therapy. Breast Cancer Res Treat. 2019;173:499–510.
https://doi.org/10.1007/s10549-018-5012-7 DOI: https://doi.org/10.1007/s10549-018-5012-7
Eliassen FM, Blåfjelldal V, Helland T, Hjorth CF, Hølland K, Lode L, et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review. BMC Cancer. 2023;23:625.
https://doi.org/10.1186/s12885-023-11122-8 DOI: https://doi.org/10.1186/s12885-023-11122-8
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized Phase III EMERALD trial. J Clin Oncol. 2022;40:3246–56.
https://doi.org/10.1200/JCO.22.00338 DOI: https://doi.org/10.1200/JCO.22.00338
Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555–65.
https://doi.org/10.1210/jc.2009-1947 DOI: https://doi.org/10.1210/jc.2009-1947
Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol. 2014;3:25–35.
https://doi.org/10.1016/j.jbo.2013.12.001 DOI: https://doi.org/10.1016/j.jbo.2013.12.001
Rogers TL, Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med. 2011;9:177.
https://doi.org/10.1186/1479-5876-9-177 DOI: https://doi.org/10.1186/1479-5876-9-177
Santini D, Stumbo L, Spoto C, D’Onofrio L, Pantano F, Iuliani M, et al. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence. Breast Cancer Res. 2015;17:121.
https://doi.org/10.1186/s13058-015-0634-8 DOI: https://doi.org/10.1186/s13058-015-0634-8
Gnant M, Clézardin P. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev. 2012;38:407–15.
https://doi.org/10.1016/j.ctrv.2011.09.003 DOI: https://doi.org/10.1016/j.ctrv.2011.09.003
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61.
https://doi.org/10.1016/S0140-6736(15)60908-4 DOI: https://doi.org/10.1016/S0140-6736(15)60908-4
Wang SF, Lin YS, Yeh WY, Chang YL, Chiang CE, Chen CH, et al. The clinical benefits of antiresorptive agents in patients with primary breast cancer receiving adjuvant endocrine therapy: a systematic review with pairwise and network meta-analysis. J Clin Endocrinol Metab. 2023;108:e1433–47.
https://doi.org/10.1210/clinem/dgad247 DOI: https://doi.org/10.1210/clinem/dgad247
O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.
https://doi.org/10.1002/14651858.CD003474.pub4 DOI: https://doi.org/10.1002/14651858.CD003474.pub4
Eisen A, Somerfield MR, Accordino MK, Blanchette PS, Clemons MJ, Dhesy-Thind S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update. J Clin Oncol. 2022;40:787–800.
https://doi.org/10.1200/JCO.21.02647 DOI: https://doi.org/10.1200/JCO.21.02647
Friedl TWP, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a Phase 3 randomized clinical trial. JAMA Oncol. 2021;7:1149–57.
https://doi.org/10.1001/jamaoncol.2021.1854 DOI: https://doi.org/10.1001/jamaoncol.2021.1854
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy tials. J Clin Oncol. 2017;35:3113–3122.
https://doi.org/10.1200/JCO.2016.72.0946 DOI: https://doi.org/10.1200/JCO.2016.72.0946
Sukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, et al. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2021;190:183–8.
https://doi.org/10.1007/s10549-021-06368-4 DOI: https://doi.org/10.1007/s10549-021-06368-4
Burr DB. Fifty years of bisphosphonates: what are their mechanical effects on bone? Bone. 2020;138:115518.
https://doi.org/10.1016/j.bone.2020.115518 DOI: https://doi.org/10.1016/j.bone.2020.115518
Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, et al. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017;18:1543–52.
https://doi.org/10.1016/S1470-2045(17)30603-4 DOI: https://doi.org/10.1016/S1470-2045(17)30603-4
Mittal A, Tamimi F, Molto C, Di Iorio M, Amir E. Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: a meta-analysis of randomized control trials. Heliyon. 2024;10:e24793.
https://doi.org/10.1016/j.heliyon.2024.e24793 DOI: https://doi.org/10.1016/j.heliyon.2024.e24793
Candido Dos Reis FJ, Wishart GC, Dicks EM, Greenberg D, Rashbass J, Schmidt MK, et al. An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. Breast Cancer Res. 2017;19:58.
https://doi.org/10.1186/s13058-017-0852-3 DOI: https://doi.org/10.1186/s13058-017-0852-3
De Groot AF, Appelman-Dijkstra NM, Van der Burg SH, Kroep JR. The anti-tumor effect of RANKL inhibition in malignant solid tumors – a systematic review. Cancer Treat Rev. 2018;62:18–28.
https://doi.org/10.1016/j.ctrv.2017.10.010 DOI: https://doi.org/10.1016/j.ctrv.2017.10.010
Gnant M, Frantal S, Pfeiler G, Steger GG, Egle D, Greil R, et al. Long-term outcomes of adjuvant denosumab in breast cancer. NEJM Evid. 2022;1:EVIDoa2200162.
https://doi.org/10.1056/EVIDoa2200162 DOI: https://doi.org/10.1056/EVIDoa2200162
Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:60–72.
https://doi.org/10.1016/S1470-2045(19)30687-4 DOI: https://doi.org/10.1016/S1470-2045(19)30687-4
Bhulani N, Wood M, Tsai J, Bedrosian I, Hopkins JO, Brunet J, et al. A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study). J Clin Oncol. 2023:40;TPS10616.
https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS10616 DOI: https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS10616
Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the penelope-B trial. J Clin Oncol. 2021;39:1518–30.
https://doi.org/10.1200/JCO.20.03639 DOI: https://doi.org/10.1200/JCO.20.03639
Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2022;40:282–93.
https://doi.org/10.1200/JCO.21.02554 DOI: https://doi.org/10.1200/JCO.21.02554
Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77–90.
https://doi.org/10.1016/S1470-2045(22)00694-5 DOI: https://doi.org/10.1016/S1470-2045(22)00694-5
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025;36(2):149–57.
https://doi.org/10.1016/j.annonc.2024.10.015 DOI: https://doi.org/10.1016/j.annonc.2024.10.015
Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M, et al. Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer. 2024;199:113555.
https://doi.org/10.1016/j.ejca.2024.113555 DOI: https://doi.org/10.1016/j.ejca.2024.113555
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer. 2024;10:34.
https://doi.org/10.1038/s41523-024-00639-1 DOI: https://doi.org/10.1038/s41523-024-00639-1
Shimoi T, Pathadka S, Sekine N, Cai Z, Tanizawa Y, Kawaguchi T, et al. Real-world data on patients with early breast cancer who were prescribed abemaciclib adjuvant therapy in Japan. Future Oncol. 2024;20:2179–88.
https://doi.org/10.1080/14796694.2024.2346464 DOI: https://doi.org/10.1080/14796694.2024.2346464
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.
https://doi.org/10.1056/NEJMoa1810527 DOI: https://doi.org/10.1056/NEJMoa1810527
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 2024;42:994–1000.
https://doi.org/10.1200/JCO.23.00137 DOI: https://doi.org/10.1200/JCO.23.00137
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307–16.
https://doi.org/10.1056/NEJMoa1903765 DOI: https://doi.org/10.1056/NEJMoa1903765
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514–24.
https://doi.org/10.1056/NEJMoa1911149 DOI: https://doi.org/10.1056/NEJMoa1911149
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942–50.
https://doi.org/10.1056/NEJMoa2114663 DOI: https://doi.org/10.1056/NEJMoa2114663
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116–24.
https://doi.org/10.1001/jamaoncol.2019.4782 DOI: https://doi.org/10.1001/jamaoncol.2019.4782
Schäffler H, Mergel F, Pfister K, Lukac S, Fink A, Veselinovic K, et al. The clinical relevance of the NATALEE study: application of the NATALEE criteria to a real-world cohort from two large German Breast Cancer Centers. Int J Mol Sci. 2023;24:16366.
https://doi.org/10.3390/ijms242216366 DOI: https://doi.org/10.3390/ijms242216366
Kanjanapan Y, Anderson W, Smith M, Green J, Chalker E, Craft P. Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors. Clin Breast Cancer. 2024;25: e159-e169.e2. DOI: https://doi.org/10.1016/j.clbc.2024.08.022
https://doi.org/10.2139/ssrn.4853788 DOI: https://doi.org/10.2139/ssrn.4853788
Houvenaeghel G, Classe JM, Chauvet MP, Colombo PE, Jouve E, Reyal F, et al. Eligibility for adjuvant cyclin-dependent kinase 4/6 inhibitors in endocrine receptor-positive and HER2-negative early breast cancer by age and type of surgery. Cancers (Basel). 2024;16:3317.
https://doi.org/10.3390/cancers16193317 DOI: https://doi.org/10.3390/cancers16193317
Loi S, Johnston S, Arteaga C, Graff S, Chandarlapaty S, Goetz M, et al. Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer. Cancer Res. 2024;84 (9_Suppl):PS06-01.
https://doi.org/10.1158/1538-7445.SABCS23-PS06-01 DOI: https://doi.org/10.1158/1538-7445.SABCS23-PS06-01
Giuliano AE, Ballman KV, McCall L, Sauvé N, Straver ME, Van de Velde CJH, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41:2159–65.
https://doi.org/10.1200/JCO.22.01565 DOI: https://doi.org/10.1200/JCO.22.01565
Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318:918–26.
https://doi.org/10.1001/jama.2017.11470 DOI: https://doi.org/10.1001/jama.2017.11470
De Boniface J, Appelgren M, Szulkin R, Alkner S, Andersson Y, Bergkvist L, et al. Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. Lancet Oncol. 2024;25:1222–30.
https://doi.org/10.1016/S1470-2045(24)00350-4 DOI: https://doi.org/10.1016/S1470-2045(24)00350-4
Williams AD, Ruth K, Shaikh SS, Vasigh M, Pronovost MT, Aggon AA, et al. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib? Cancer. 2024;130:1052–60.
https://doi.org/10.1002/cncr.35136 DOI: https://doi.org/10.1002/cncr.35136
Gaillard T, Piketty J, Feron JG, Girard N, Pauly L, Gauroy E, et al. Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib. Br J Cancer. 2024;130:1141–8.
https://doi.org/10.1038/s41416-024-02580-3 DOI: https://doi.org/10.1038/s41416-024-02580-3
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134–47. DOI: https://doi.org/10.1016/j.yobg.2012.05.049
https://doi.org/10.1158/1055-9965.EPI-11-0775 DOI: https://doi.org/10.1158/1055-9965.EPI-11-0775
Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008;26:246–52.
https://doi.org/10.1200/JCO.2007.11.5352 DOI: https://doi.org/10.1200/JCO.2007.11.5352
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, et al. Patient-reported outcomes in OlympiA: a Phase III, randomized, placebo-controlled trial of adjuvant plaparib in gBRCA1/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer. J Clin Oncol. 2024;42:1288–300.
https://doi.org/10.1200/JCO.23.01214 DOI: https://doi.org/10.1200/JCO.23.01214
Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline. J Clin Oncol. 2024;42:584–604.
https://doi.org/10.1200/JCO.23.02225 DOI: https://doi.org/10.1200/JCO.23.02225
Li X, You R, Wang X, Liu C, Xu Z, Zhou J, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22:3971–81.
https://doi.org/10.1158/1078-0432.CCR-15-1465 DOI: https://doi.org/10.1158/1078-0432.CCR-15-1465
Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80–7.
https://doi.org/10.1093/jnci/djn442 DOI: https://doi.org/10.1093/jnci/djn442
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.
https://doi.org/10.1001/jama.292.11.1317 DOI: https://doi.org/10.1001/jama.292.11.1317
Demedt C, Turner N, Arteaga C, Sasano H, Graff SL, Loi S, et al. Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE. Ann Oncol. 2024;9(suppl_4):1–34.
https://doi.org/10.1016/j.esmoop.2024.103013 DOI: https://doi.org/10.1016/j.esmoop.2024.103013
Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, et al. PARP inhibitors for breast cancer treatment: a review. JAMA Oncol. 2024;10:658–70.
https://doi.org/10.1001/jamaoncol.2023.7322 DOI: https://doi.org/10.1001/jamaoncol.2023.7322
Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025;31:442–8.
https://doi.org/10.1038/s41591-024-03415-7 DOI: https://doi.org/10.1038/s41591-024-03415-7
Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21:1155–64.
https://doi.org/10.1016/S1470-2045(20)30324-7 DOI: https://doi.org/10.1016/S1470-2045(20)30324-7
Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, et al. Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer. Clin Cancer Res. 2024;30:1240–7.
https://doi.org/10.1158/1078-0432.CCR-23-2513 DOI: https://doi.org/10.1158/1078-0432.CCR-23-2513
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). J Immunother Cancer. 2023;11:e007126.
https://doi.org/10.1136/jitc-2023-007126 DOI: https://doi.org/10.1136/jitc-2023-007126
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423–33.
https://doi.org/10.1016/S0140-6736(23)01245-X DOI: https://doi.org/10.1016/S0140-6736(23)01245-X
Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Final results from the randomized Phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024;42:1738–44.
https://doi.org/10.1200/JCO.23.01409 DOI: https://doi.org/10.1200/JCO.23.01409
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O’Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110–22.
https://doi.org/10.1056/NEJMoa2407086 DOI: https://doi.org/10.1056/NEJMoa2407086
Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30:2208–15.
https://doi.org/10.1038/s41591-024-03021-7 DOI: https://doi.org/10.1038/s41591-024-03021-7
Sra MS, Sasi A, Batra A, Bakhshi S, Ganguly S. Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk hormone receptor-positive early breast cancer: an Indian perspective. JCO Glob Oncol. 2024;10:e2300433.
https://doi.org/10.1200/GO.23.00433 DOI: https://doi.org/10.1200/GO.23.00433
Jenei K, Raymakers AJN, Bayle A, Berger-Thürmel K, Cherla A, Honda K, et al. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol. 2023;24:624–35.
https://doi.org/10.1016/S1470-2045(23)00175-4 DOI: https://doi.org/10.1016/S1470-2045(23)00175-4
Vanderpuye V, Dadzie MA, Huo D, Olopade OI. Assessment of breast cancer management in sub‐Saharan Africa. JCO Glob Oncol. 2021;7:1593–1601.
https://doi.org/10.1200/GO.21.00282 DOI: https://doi.org/10.1200/GO.21.00282
Carlson RW, Anderson BO, Chopra R, Eniu AE, Jakesz R, Love RR, et al. Treatment of breast cancer in countries with limited resources. Breast J. 2003;9(Suppl 2):S67–74.
https://doi.org/10.1046/j.1524-4741.9.s2.6.x DOI: https://doi.org/10.1046/j.1524-4741.9.s2.6.x
Nicoletti AP, Damin AP. Factors influencing the first and the fifth years adherence to adjuvant endocrine therapy in breast cancer patients in a low income country. Breast Cancer Res Treat. 2024;204:599–606.
https://doi.org/10.1007/s10549-023-07221-6 DOI: https://doi.org/10.1007/s10549-023-07221-6
Elshafie S, Trivedi R, Villa-Zapata LA, Tackett RL, Zaghloul IY, Young HN. Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: a systematic review and meta-analysis. Cancer. 2025;131:e35550.
https://doi.org/10.1002/cncr.35550 DOI: https://doi.org/10.1002/cncr.35550
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non‐adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37.
https://doi.org/10.1007/s10549-010-1132-4 DOI: https://doi.org/10.1007/s10549-010-1132-4
Gianni C, Nicolò E, Cristofanilli M. Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all? Transl Breast Cancer Res. 2024;5:34.
https://doi.org/10.21037/tbcr-24-41 DOI: https://doi.org/10.21037/tbcr-24-41
Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970–86.
https://doi.org/10.1016/j.annonc.2023.08.017 DOI: https://doi.org/10.1016/j.annonc.2023.08.017
Al Sukhun S, Temin S, Barrios CH, Antone NZ, Guerra YC, Chavez-MacGregor M, et al. Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2024;10:e2300285.
https://doi.org/10.1200/GO.23.00411 DOI: https://doi.org/10.1200/GO.23.00411
Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, et al. The global breast cancer initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol. 2021;22(5):578–81.
https://doi.org/10.1016/S1470-2045(21)00071-1 DOI: https://doi.org/10.1016/S1470-2045(21)00071-1
Mensah S, Kyei I, Agbedinu K, Shiako J, Yorke DA, Gyedu A. Assessing breast cancer diagnosis and management in Ghana per the global breast cancer initiative key performance indicators. JCO Glob Oncol. 2025;11:e2400653.
https://doi.org/10.1200/GO-24-00653 DOI: https://doi.org/10.1200/GO-24-00653
Boucheron P, Zietsman A, Anele A, Offiah AU, Galukande M, Parham G, et al. Measuring the WHO global breast cancer initiative pillars’ key performance indicators in sub-Saharan Africa: experience in the African Breast Cancer-Disparities in Outcomes hospital-based cohort study. EClinicalMedicine. 2025;81:103104.
https://doi.org/10.1016/j.eclinm.2025.103104 DOI: https://doi.org/10.1016/j.eclinm.2025.103104
Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012;367:1998–2005.
https://doi.org/10.1056/NEJMoa1206809 DOI: https://doi.org/10.1056/NEJMoa1206809
Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjær H, Holford TR, et al. The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model. Cancer Epidemiol Biomarkers Prev. 2015;24:905–12.
https://doi.org/10.1158/1055-9965.EPI-14-1286 DOI: https://doi.org/10.1158/1055-9965.EPI-14-1286
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023;34:33–47.
https://doi.org/10.1016/j.annonc.2022.10.004 DOI: https://doi.org/10.1016/j.annonc.2022.10.004
Fasching PA, Stroyakovskiy D, Yardley D, Huang C-S, Crown JP, Bardia A, et al. Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Ann Oncol 2024;35(Suppl 2):S1207.https://doi.org/10.1016/j.annonc.2024.08.2251 DOI: https://doi.org/10.1016/j.annonc.2024.08.2251
Geyer CE Jr, Garber JE, Gelber RD, Klimberg VS, Roshal JA, Yuan T, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68.
https://doi.org/10.1016/j.annonc.2022.09.159 DOI: https://doi.org/10.1016/j.annonc.2022.09.159
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Peeter Karihtala
This work is licensed under a Creative Commons Attribution 4.0 International License.
